Abilitypharma Is A Clinical Stage Biopharmaceutical Company Based In Cerdanyola Del Valla Scataloniaspainthe Company Focuses On Developing Innovative Therapies That Target Autophagy For Cancer Treatmentits Approach Aims To Selectively Induce Cancer Cell Death While Preserving Healthy Cellssetting It Apart From Traditional Cancer Therapies The Lead Candidateabtl0812Is An Oral Small Molecule Drug Currently In A Phase 2B Trial For Metastatic Pancreatic Cancerwith Active Recruitment Of 140 Patients Across The U S Spainfranceand Israelprevious Phase 2A Trials Have Shown Efficacy In Treating Endometrial Cancer And Squamous Non Small Cell Lung Cancerabilitypharma S Pipeline Addresses Significant Unmet Needs In Oncologyparticularly For Aggressive Cancers With Limited Treatment Options The Company Emphasizes Translational Research To Connect Preclinical Findings With Clinical Outcomeswith A Valuation Of $30 Million And A History Of Fundingabilitypharma Is Positioned As A Pioneer In Autophagy Based Oncologyaiming To Establish A New Therapeutic Paradigm Through Its First In Class Candidates
United States
